Rhino-cerebral mucormycosis in patients with COVID-19: clinical cases and treatment in a regional hospital

Mucormycosis is a serious fungal infection, which increased significantly during the COVID-19 pandemic. We retrospectively analyzed 5 histopathologically confirmed cases of rhino-cerebral mucormycosis, which were diagnosed in patients admitted to Smolensk regional clinical hospital from November 2021 to January 2022. All patients were older than 60 years of age and had a recent history of laboratoryconfirmed severe COVID-19 and were treated in infection hospitals. All patients had decompensated type 2 diabetes mellitus; 80% of patients had concomitant cardiovascular diseases (coronary heart disease, arterial hypertension), 100% of patients received previous treatment with systemic corticosteroids for COVID-19 in hospitals. All patients underwent surgical treatment. Antifungal therapy (amphotericin B) was administered, and one patient received posaconazole due to a lack of efficacy of amphotericin B. The length of hospital stay ranged from 14 to 56 days. The overall 3-month survival rate of patients with rhinocerebral mucormycosis was 80%

DIMENSIONAL CHARACTERISTICS OF MAMMAS OF GIRLS-SLAVS OF 17–20 YEARS

In work quantitative data about a circle, cross-section (transversal) both longitudinal diameters of the establishment and height of a body of a mamma, length submammary cords (crimps), diameters and height of a papilla (papilla mammaria) and diameter of a peripapillary circle (areola mammae) at girls-Slavs of 17-20 years (n = 228) for the first time are presented

Community-acquired pneumonia in HIV patients

The objective: To study the frequency and nature of community-acquired pneumonia (CAP) in HIV patients. Subjects and methods: The continuous longitudinal retrospective study of all cases of respiratory diseases among HIV patients (n = 185), who received in-patient treatment in the therapy department. Results. CAP was diagnosed in 38.4% (n = 71) of patients and it was the most frequent respiratory disease among HIV patients. The median CD4 count in CAP made 197.5 cells/μL, 9.1% of patients received antiretroviral therapy before hospital admission. 74.7% of CAP patients (n = 53) had lesions disseminated to several lobes. Laboratory parameters revealed in severe CAP (leukocytosis > 12 × 109/L, leukopenia 0.05). Bacteremia in CAP was detected in 20.8% of patients and it was associated with the failure of standard empiric antibiotic therapy (p < 0.05). 9.9% of CAP patients (n = 7) were diagnosed with polymicrobial infection. Lethal outcomes of CAP were recorded in 5.6% of cases (n = 4), all with severe immunosuppression (the median of CD4 count was 5 cells/μL), 2 cases had bilateral subtotal CAP and 2 suffered from polymicrobial infection. © 2021 New Terra Publishing House. All rights reserved

Clinical efficacy of dry nutritional treatment products for phenylketonuria in children, adults, and pregnant women: study results

N.A. Semenova1, G.V. Baydakova1, N.V. Nikitina2, V.K. Podolina2, E.Yu. Belyashova3,&nbsp;V.N. Kuznetsova3, E.M. Kochegurova4, L.P. Andreeva5, O.N. Khaylova5, S.I. Kutsev1 1Research Centre for Medical Genetics, Moscow, Russian Federation 2Clinical and Diagnostic Center “Protection of Health of Mother and Child”, Yekaterinburg, Russian Federation 3Orenburg Regional Clinical Hospital No. 2, Orenburg, Russian Federation 4E.M. Bakunina Regional Clinical Perinatal Center, Tver, Russian Federation 5Saratov Regional Children’s Clinical Hospital, Saratov, Russian Federation Abstract Aim: to assess the efficacy of domestic nutritional treatment products for phenylketonuria (PKU) in children, adults, and pregnant women. Patients and Methods: 46 patients with verified PKU were enrolled in this open-label multicenter prospective non-controlled study. Patients were allocated to the groups depending on nutritional treatment products which were prescribed according to the Clinical Guidelines of the Ministry of Health of Russian Federation. Clinical efficacy of the products was assessed according to the Good Clinical Practice guidelines based on clinical and laboratory tests. Results: all patients taken nutritional treatment products throughout the study. No dyspepsia, abnormal poop, or allergic reactions were reported. Most patients reported on more pleasant smell and odor of the products as compared with the products taken previously. At baseline, mean phenylalanine levels were within normal limits. After the treatment, phenylalanine levels were stable&nbsp; in all patients. Clinical and biochemical tests were within normal limits. Conclusion: dry nutritional treatment products are highly effective in children, adults, and pregnant women with PKU. Keywords: phenylketonuria, specialized food, phenylalanine, mixture, products. For citation: Semenova N.A., Baydakova G.V., Nikitina N.V. et al. Clinical efficacy of dry nutritional treatment products for phenylketonuria in children, adults, and pregnant women: study results. Russian Journal of Woman and Child Health. 2019;2(4):355–360. <br